Yinfenidone clinical trials
Also written HEC585.
How each study uses yinfenidone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the yinfenidone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HEC585
- 6
Studies by the year they started
6 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses yinfenidone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Confirmatory Clinical Study of HEC585 Tablets in Patients With IPFRecruitingPhase 3Sunshine Lake Pharma Co., Ltd.NCT07082842Written as HEC585
- Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy SubjectsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT07588646Written as HEC585
- Phase ll Study of HEC585 in Patients With IPFActive, not recruitingPhase 2Sunshine Lake Pharma Co., Ltd.NCT05060822Written as HEC585
- To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy VolunteersCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT05383131Written as HEC585
- Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female SubjectsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT04512170Written as HEC585
- The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female SubjectsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT03092102Written as HEC585